Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Terns Pharmaceuticals (TERN)
NASDAQ:TERN
RESEARCH TOOLSreports
Holding TERN?
Track your performance easily
TERN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.30 - $11.40
Previous Close$7.46
Volume1.14M
Average Volume (3M)1.96M
Market Cap
$629.89M
Enterprise Value$404.84M
Total Cash (Recent Filing)$225.30M
Total Debt (Recent Filing)$249.00K
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Apr 01, 2025EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding70,371,911
10 Day Avg. Volume1,158,075
30 Day Avg. Volume1,956,471
Standard Deviation0.29
R-Squared0.00296
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)2.13
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.88
Forecast
1Y Price Target
$21.20Price Target Upside195.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Terns Pharmaceuticals News
PremiumCompany Announcements
Terns Pharmaceuticals Reports Q3 Progress and Financials
PremiumStock Analysis & Ideas
Insiders Snap Up These 2 ‘Strong Buy’ Stocks
Bulls Say, Bears Say
Bulls Say
Market PotentialAnalysts remain quite bullish on TERN-701, acknowledging the long-term potential of the CML market opportunity.
Product Development And DifferentiationThe food effect profile for '701 is a potential key differentiator for it vs. other approved CML drugs.
Valuation And Risk-RewardAnalyst reiterates an Outperform rating on TERN, seeing a compelling risk-reward with approximately 60% upside to the new price target.
Bears Say
Clinical TrialsThe Phase 1 data for ELVN-001 are still relatively early in terms of both efficacy and safety, with longer-term study and data needed to fully inform the candidate's ultimate clinical profile.
Financial PerformanceTERN reported a net loss of $22.7 million, highlighting financial challenges that may impact future operations and investor confidence.
Management ChangesOngoing changes to the management team include the departure of Bryan Yoon (COO) and Mark Vignola (CFO), indicating potential instability or strategic shifts within the company.
---
Ownership Overview
16.37% Insiders
7.60% Mutual Funds
1.44% Other Institutional Investors
66.13% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TERN FAQ
What was Terns Pharmaceuticals’s price range in the past 12 months?
Terns Pharmaceuticals lowest stock price was $3.30 and its highest was $11.40 in the past 12 months.
What is Terns Pharmaceuticals’s market cap?
Currently, no data Available
When is Terns Pharmaceuticals’s upcoming earnings report date?
Terns Pharmaceuticals’s upcoming earnings report date is Apr 01, 2025 which is in 135 days.
How were Terns Pharmaceuticals’s earnings last quarter?
Terns Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.32 by $0.04.
Is Terns Pharmaceuticals overvalued?
According to Wall Street analysts Terns Pharmaceuticals’s price is currently Undervalued.
Does Terns Pharmaceuticals pay dividends?
Terns Pharmaceuticals does not currently pay dividends.
What is Terns Pharmaceuticals’s EPS estimate?
Terns Pharmaceuticals’s EPS estimate is -$0.32.
How many shares outstanding does Terns Pharmaceuticals have?
Terns Pharmaceuticals has 84,435,960 shares outstanding.
What happened to Terns Pharmaceuticals’s price movement after its last earnings report?
Terns Pharmaceuticals reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.32. Following the earnings report the stock price went up 0.976%.
Which hedge fund is a major shareholder of Terns Pharmaceuticals?
Among the largest hedge funds holding Terns Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds Terns Pharmaceuticals’s shares valued at 7M.
---
Terns Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.20 (195.68% Upside)
$21.20 (195.68% Upside)
Blogger Sentiment
Bullish
TERN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 572.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
111.93%
12-Months-Change
Fundamentals
Return on Equity
-38.92%
Trailing 12-Months
Asset Growth
-20.30%
Trailing 12-Months
Company Description
Terns Pharmaceuticals
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.
---
TERN Stock 12 Month Forecast
Average Price Target
$21.20
▲(195.68% Upside)
Technical Analysis
Best Analysts Covering TERN
1 Year
1 Year Success Rate
8/10 ratings generated profit
1 Year Average Return
+19.38%
reiterated a buy rating 2 months ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +19.38% per trade.
---